Two Sigma Advisers LP Purchases Shares of 46,029 Horizon Pharma PLC (HZNP)

Two Sigma Advisers LP purchased a new stake in Horizon Pharma PLC (NASDAQ:HZNP) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 46,029 shares of the biopharmaceutical company’s stock, valued at approximately $672,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in shares of Horizon Pharma by 18.6% in the third quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock valued at $94,254,000 after purchasing an additional 1,167,722 shares during the period. Brandywine Global Investment Management LLC raised its position in shares of Horizon Pharma by 3.7% in the fourth quarter. Brandywine Global Investment Management LLC now owns 4,160,474 shares of the biopharmaceutical company’s stock valued at $60,743,000 after purchasing an additional 149,854 shares during the period. Renaissance Technologies LLC raised its position in shares of Horizon Pharma by 105.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,279,400 shares of the biopharmaceutical company’s stock valued at $33,279,000 after purchasing an additional 1,170,000 shares during the period. Geode Capital Management LLC raised its position in shares of Horizon Pharma by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,512,858 shares of the biopharmaceutical company’s stock valued at $22,087,000 after purchasing an additional 23,950 shares during the period. Finally, Armistice Capital LLC raised its position in shares of Horizon Pharma by 25.0% in the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $14,600,000 after purchasing an additional 200,000 shares during the period. 86.55% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

Horizon Pharma stock opened at $13.66 on Wednesday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.54 and a current ratio of 1.63. The company has a market cap of $2,260.17, a P/E ratio of 11.58, a PEG ratio of 0.58 and a beta of 1.24. Horizon Pharma PLC has a 1-year low of $9.45 and a 1-year high of $16.02.

Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.07. The business had revenue of $274.22 million for the quarter, compared to analyst estimates of $264.48 million. Horizon Pharma had a negative net margin of 38.87% and a positive return on equity of 18.44%. Horizon Pharma’s revenue was down 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.64 EPS. research analysts expect that Horizon Pharma PLC will post 1.43 EPS for the current year.

Several research firms have recently issued reports on HZNP. Cantor Fitzgerald set a $17.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a research report on Monday, January 8th. BidaskClub raised shares of Horizon Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, March 28th. UBS set a $20.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a report on Thursday, March 1st. Finally, ValuEngine lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. Horizon Pharma currently has an average rating of “Buy” and an average price target of $18.64.

TRADEMARK VIOLATION WARNING: “Two Sigma Advisers LP Purchases Shares of 46,029 Horizon Pharma PLC (HZNP)” was published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://weekherald.com/2018/04/18/two-sigma-advisers-lp-purchases-shares-of-46029-horizon-pharma-plc-hznp.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply